atropine sulfate
Sensory organs (S01)US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
pharma · Non-muscle Invasive Bladder Cancer · Non-Muscle Invasive Bladder Cancer
ImmunityBio
Immunitybio Ireland Limited
ImmunityBio drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
San Diego, USA HQ
2014 Founded
625 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- San Diego, USA
- Founded
- 2014
- Employees
- 625
- Programs
- 2
- Drugs
- 5
- Patents
- 0
ImmunityBio pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
ImmunityBio drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
Development asset linked to ImmunityBio in public FDA and regional records.
-
Development asset linked to ImmunityBio in public FDA and regional records.
-
Development asset linked to ImmunityBio in public FDA and regional records.